Method Article

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

1.4K views

⸱

DOI:

10.3791/68367

⸱

August 1st, 2025

 ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , 
1Department of Molecular Biotechnology and Health Science, University of Torino, 2Department of Science and Technological Innovation, University of Piemonte Orientale, 3Division of Urology, Department of Surgical Sciences, University of Turin, 4Department of Surgical Sciences and Urology, Città della Salute e della Scienza di Torino, University of Turin, 5Department of Pathology, University of Turin, and AOU Città della Salute e della Scienza

In This Article

Summary

This protocol provides a comprehensive procedure to isolate, expand, and immortalize fibroblasts from radical prostatectomies. Moreover, it describes assays developed to assess the functional effects of fibroblast-tumor cell crosstalk, taking advantage of both treatment with conditioned medium and co-culturing.

Abstract

Tumor stroma can be actively shaped by tumor cells to adopt pro-tumorigenic properties, making it a focal point of cancer research. Among the stromal components, cancer-associated fibroblasts (CAFs) -- often the most abundant cell type in the tumor microenvironment (TME) -- play a pivotal role in promoting cancer progression through their interactions with tumor cells and other stromal components. Elucidating the mechanisms behind these interactions requires robust methods for isolating and characterizing CAFs, which can also lay the foundation for developing novel CAF-targeted cancer therapies. This study presents a method for isolating fibroblasts from both the tumor and the adjacent normal regions of radical prostatectomy specimens obtained from prostate cancer (PCa) patients. This approach enables the concurrent isolation of CAFs and their normal counterparts (NFs) from the same individual, providing a paired experimental system. Detailed protocols are provided for the maintenance of primary CAFs and NFs for downstream in vitro analyses, as well as for their immortalization to facilitate long-term studies. We also describe functional assays designed to compare the effects of CAFs and NFs on cancer cell behaviors, including proliferation, migration, and anchorage-independent growth. Two complementary approaches are detailed: treatment of cancer cells with fibroblast-derived conditioned media (CM), and direct co-culture of fibroblasts with tumor cells. Together, these methodologies represent a comprehensive toolkit for investigating the dynamic interplay between CAFs and tumor cells, not only in PCa but potentially across a range of human cancers. Moreover, molecular characterization of these interactions may reveal key mediators of CAF-driven oncogenesis, offering promising targets for therapeutic intervention.

Introduction

Prostate cancer (PCa) is the most frequently diagnosed cancer in men across nearly two-thirds of countries worldwide. In 2022, approximately 1.5 million new cases were reported, resulting in 3,97,000 deaths globally. These figures make PCa the second most common cancer and the fifth leading cause of cancer-related mortality among men1.

PCa is a multifocal and biologically complex disease, marked by substantial intertumoral heterogeneity2,3,4, diverse molecular subtypes, and variable clinical outcomes5,6, all of which significantly influence prognosis and therapeutic response7.

While the critical role of the tumor microenvironment (TME) in prostate tumor initiation and progression is well established8,9, the molecular interactions between tumor cells and the surrounding stromal compartment remain incompletely understood. While it is well established that the prostate tumor microenvironment (TME) plays a critical role in tumor initiation and progression, the molecular interactions between tumor cells and the surrounding stroma remain insufficiently defined. The TME comprises a variety of stromal cells, including those of mesenchymal and immune origin, which become activated in response to tumor-derived signals and subsequently acquire tumor-promoting functions10,11. Among these, cancer-associated fibroblasts (CAFs) often represent the most abundant stromal population. CAFs contribute to extracellular matrix (ECM) remodeling, promote tumor growth, and facilitate cancer cell invasion and migration4,11,12,13. Through secreted factors and direct cell-cell interactions, CAFs also influence proliferation, invasion, and therapy resistance. Notably, CAFs are a heterogeneous population. While generally associated with pro-tumorigenic functions, some subtypes may exert tumor-suppressive roles14,15. Importantly, the absence of unique markers for CAFs poses challenges for their precise identification and the functional dissection of their diverse roles12,16.

A robust approach to investigate the functional crosstalk between CAFs and tumor cells involves isolating primary CAFs and matched normal fibroblasts (NFs), then assessing their respective influence on tumor cell behaviors such as proliferation, migration, colony formation, and anchorage-independent growth17,18,19. This article describes a refined, highly reproducible protocol for isolating CAFs and NFs from radical prostatectomy specimens of high-risk PCa patients. A critical component of this protocol is the accurate identification and dissection of tumor and tumor-free regions by an expert uropathologist, allowing the derivation of CAFs and NFs from the same patient. This paired-sample approach helps control for intertumoral heterogeneity and individual patient-specific variables that can influence fibroblast phenotypes20,21,22. To ensure sufficient tumor tissue is available, we focus on specimens from patients with a Gleason score ≥7.

Reliable phenotypic characterization of the isolated fibroblasts requires the use of multiple markers to distinguish them from other cell types, particularly epithelial cells, which may share overlapping marker expression16. As primary PCa fibroblasts typically undergo senescence after 10-15 passages, complicating long-term analyses, we also present a protocol for cell immortalization via stable expression of the human telomerase reverse transcriptase (hTERT)23.

To explore the functional effects of CAFs and NFs on tumor cells, we tested and optimized several experimental strategies. Given that CAFs exert their influence through both secreted factors and direct cell-cell contact24, two complementary assay systems are developed: (1) treatment of cancer cells with fibroblast-conditioned medium (CM), and (2) direct co-culture of fibroblasts and tumor cells. These assays evaluate key cancer cell properties, including proliferation, anchorage-independent growth, and migration. To standardize the influence of secreted factors, conditioned media from CAFs and NFs were concentrated and quantified (conCM) based on total protein content.

Demonstrating significant functional effects through these assays can support the identification of critical mediators of CAF-driven tumorigenesis, offering potential targets for therapeutic intervention.

Access restricted. Please log in or start a trial to view this content.

Protocol

This study was conducted in full compliance with Institutional guidelines for the use of clinical samples, as approved by the Bioethical Committee of the Città della Salute Molinette Hospital in Turin, Italy. All samples were obtained following the signing of informed consent by participating patients. The following section provides a detailed, step-by-step protocol for the isolation of cancer-associated fibroblasts (CAFs) and their matched normal fibroblast (NF) counterparts. The protocol includes dissection of the tumor and adjacent non-tumorous areas, tissue processing, cell culture, and both phenotypic and functional characterization of the isolated cells. All procedures must be performed under sterile conditions within a certified biosafety cabinet. Cells were cultured at 37 °C in a humidified atmosphere containing 5% CO2 using complete Dulbecco's Modified Eagle Medium (cDMEM), supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin, unless stated otherwise. All centrifugation steps are carried out with the brake engaged. Refer to the Table of Materials for a comprehensive list of reagents, materials, and equipment used throughout the protocol. This methodology has been optimized for high-risk prostate cancer specimens, with a Gleason score of 4+3 or higher.

1. Surgical sample dissection

NOTE: This procedure was performed on surgical specimens collected from radical prostatectomy procedures25 performed on patients with high-grade prostate cancer (PCa), and managed following standardized protocols, based on internal institutional guidelines and established international literature and best practices26,27,28.

  1. Place the prostate gland under a biosafety hood on a sterile drape, and orient it according to anatomical landmarks.
    NOTE: This procedure must be performed by an experienced uropathologist.
  2. Using a sterile blade, excise tissue slices from areas identified in the preoperative biopsy report as being neoplastic or free of tumor cells.
  3. Conduct a rapid cryostatic analysis29 on both tissue samples, by preparing 2.5-µm-thick tissue sections and staining them with hematoxylin and eosin (H&E) to verify the presence or absence of tumor cells in the selected regions, in accordance with the diagnostic criteria for prostatic adenocarcinoma of the latest edition of the WHO classification30 (see Figure 1A).
    NOTE: If discrepancies arise, repeat the sampling process until histological confirmation of both neoplastic and non-neoplastic areas is obtained.
  4. Excise approximately 10 mm2 samples from the neoplastic and non-neoplastic regions, place them in 15 mL conical tubes containing 7 mL of ice-cold Tissue Storage buffer, and keep them on ice for subsequent procedures.
    NOTE: Samples can be stored at 4 °C for up to 48 h in this buffer.

2. Fibroblasts isolation

NOTE: All following processing procedures must be performed on ice at 4 °C unless otherwise mentioned. See Figure 1 A for a scheme.

  1. Day 1: Weigh the tissue samples.
    NOTE: 70-100 mg are obtained on average.
  2. Move to 6 cm dishes and perform four sequential washes, twice in 4 mL of ice-cold PBS and twice in 4 mL of ice-cold cDMEM, both supplemented with 200 U/mL Penicillin, 200 µg/mL Streptomycin (2x), using sterile forceps to transfer the tissue from one dish to the next.
  3. Mechanically disrupt the tissue by placing it in a 6 cm plate on ice, with 1 mL of DMEM supplemented with 100 U/mL penicillin-G and 100 µg/mL streptomycin, then mince it into small fragments (<1 mm2) using scissors or blades.
  4. Transfer to a 15 mL conical tube containing 5 mL of ice-cold cDMEM. Centrifuge at 754 x g for 5 min at 4 °C.
  5. Use a 10 mL pipette to carefully remove the supernatant and resuspend the pellet in 5 mL of ice-cold cDMEM. Centrifuge again at 754 x g for 5 min at 4 °C.
  6. Remove supernatant as above and resuspend the pellet in Collagenase II (1mg/mL in DMEM), using 1 mL/100 mg of tissue. Move to a 1.5 mL microtube.
    NOTE: Due to the variability of Collagenase batches, test different batches and ensure that they have enough to perform all predicted isolations.
  7. Cover the tubes with paraffin film and digest samples O/N (8-12 h) at 37 °C with continuous rocking.
    NOTE: Perform the following steps on Day 2.
  8. Transfer the samples into 15 mL conical tubes and add 5 mL of ice-cold cDMEM to the cell suspension to inactivate collagenase, then centrifuge at 754 x g for 5 min at 4 °C.
    NOTE: Collagenase is disposed of by aspirating it into a detergent-containing container.
  9. Aspirate the supernatant using a 10 mL pipette and resuspend the pellet in 1 mL of 0.05% Trypsin/EDTA. Incubate for 5 min at 37 °C, shaking occasionally.
  10. Add 1 mL of DNase I to the samples and mix well. Use a freshly prepared 25 mg/mL solution in PBS.
    NOTE: DNase I treatment at this stage helps obtain the single-cell solution.
  11. Centrifuge at 754 x g for 5 min at 4 °C.
  12. Use a 10 mL pipette to aspirate the supernatant, and resuspend the pellet in 5 mL of cold cDMEM. Centrifuge at 754 x g for 5 min 4 °C.
  13. Resuspend cells in 20% FBS cDMEM. Plate and incubate at 37 °C, 5% CO2, and 95% humidity for at least 3 days. Take care not to move/tilt the dish. For 70-100 mg of tissue, distribute the cell suspension in 2 x 3.5 cm dishes, in 2 mL of medium. Downscale accordingly if necessary.
    NOTE: Less than 50 mg of tissue will result in inefficient cell derivation. The splitting and freezing scheme is shown in Figure 1B.
  14. After 3 days, check cells for morphology/viability and replace 2/3 of the medium to maintain cell-produced growth factors. It will take about 7-10 days for the cells to reach confluency, replacing the medium every other day.
  15. Once confluent, passage the cells into one 10 cm dish in 20% FBS cDMEM.
  16. Replace the medium every other day, using 15% FBS medium twice, then once, 12.5%, then 10%. For FACS analyses, RNA and protein extraction and freezing stocks follow the scheme in Figure 1B.
  17. Split cells when about 100% confluent (about 10 days). Wash 2-3 times with abundant PBS for 5 min each. Add 1% Trypsin/EDTA (2x) and place in the incubator, checking for cell detachment every few minutes.

3. Culturing condition

  1. Passage the cells only when 100% confluent, no more than 1:3.
  2. Freeze aliquots corresponding to 50% of a confluent 10 cm dish in 0.5 mL of ice-cold freezing medium (10% DMSO in FBS). Thaw each aliquot in a 10 cm dish.
    NOTE: The average doubling time is 80-90 h.

4. FACS analysis

NOTE: This protocol ensures reliable characterization of the fibroblast population and identifies potential contamination from epithelial, endothelial, or immune cells. FACS analysis is performed in passage 2, as illustrated in Figure 2A.

  1. Harvest cells and resuspend them in FACS buffer (PBS plus 2% FBS) at a concentration of 106 cells/mL.
  2. Label flow cytometry tubes and add 1 x 105 cells in a 100 µL volume in each of them. For staining with 4 antibodies, prepare 11 tubes to account for both staining and gating, as follows (Table 1)
    NOTE: 1 tube, no antibodies (unstained control), to assess cell autofluorescence, 1 tube with antibody isotype control, to assess aspecific binding, 4 tubes, each with a single antibody, for compensation; compensation beads can replace cells, 4 Fluorescence Minus One (FMO) tubes for gating, each leaving out one of the antibodies, 1 tube with all 4 antibodies (actual sample). The following fluorescently labeled antibodies are used (see Table of Materials): (1) Anti-EpCAM-PE (Epithelial cell marker), (2) Anti-CD31-VioBlue (Endothelial cell marker), (3) Anti-CD45-FITC (Immune cell marker), (4) Anti-CD90-APC (Fibroblast cell marker). Antibodies conjugated to other fluorophores may be used, according to available flow cytometer filters. Perform all steps on ice to preserve cell viability.
  3. Incubate cells with Fragment Crystallizable receptors (FcR) blockers, such as purified anti-CD16/CD32 antibodies or blocking buffer (PBS 1%-2% BSA). Use 1-5 µL FcR Blocking Reagent per 100 µL of cell suspension, and incubate at 4 °C for 10-15 min.
  4. Proceed directly with the staining without washing. Add appropriate antibody dilutions or the corresponding isotype controls to the tubes, as specified in Table 1.
  5. Gently mix and incubate at 4 °C in the dark for 30 min.
  6. Wash with 2 mL of FACS buffer.
  7. Centrifuge for 5 min at 300 x g, at 4 °C.
  8. Discard the supernatant and resuspend cells in 1 mL of fresh FACS buffer.
  9. Add viability dye (propidium iodide) according to manufacturer's instructions (see Table of Materials).
  10. Acquire the samples on a flow cytometer.
  11. Use single-stained compensation controls to set up the compensation matrix. For data analysis, apply the following gating strategy on FACS density plots:
  12. Forward and side scatter gating: plot FSC-A vs. SSC-A and design a region around the main cell population to exclude cellular debris.
  13. For doublet exclusion: plot FSC-A vs. FSC-W (or FSC-H vs. FSC-A) and design a region to exclude clumps of cells, which will show increased width relative to the area (or increased area relative to the height). Select the single cells and perform the same procedure, plotting SSC-A vs. SSC-W (or SSC-H vs. SSC-A) to increase the purity of the single cell's population.
  14. Plot the viability dye (i.e., propidium iodide) vs. SSC-A and select negative live cells.
  15. On live cells, plot CD326 (x-axis) vs. CD31 (y-axis); use the corresponding FMO samples to accurately set gates. FMO allows one to account for the spread of fluorescence into a specific channel caused by the other fluorophores.
    1. Looking at the CD326 FMO sample, draw a quadrant gate that includes all cells in the left quadrants (i.e., negative for CD326). Repeat the same procedure using the CD31 FMO sample to adjust the gate in order to have all the FMO cells in the lower quadrants (i.e., negative for CD31). Use this quadrant to analyze the samples, and select cells in the lower left quadrant (CD31- CD326-).
  16. Repeat the same procedure plotting CD326 (x-axis) vs. CD45 (y-axis), using the CD326 FMO and the CD45 FMO to set the quadrant gate. Use this quadrant to analyze all the samples and select cells in the lower left quadrant (CD45- CD326-).
  17. Plot CD90 vs. SSC-A and use the CD90 FMO to set a region that excludes negative cells and includes only CD90+. Use this region to analyze all the samples, measuring the percentage of CD90+ cells. Representative results are shown in Figure 2A.

5. Fibroblasts immortalization

NOTE: Immortalization of CAF and NF populations is achieved by stable transduction with an hTERT-expressing retroviral vector. Below are the protocols to prepare infective pseudoviral particles and transduce cells.

  1. Retroviral particles production
    1. Day 1, poly-L-lysine coating and cells plating: Coat a 10 cm dish with 6 mL of poly-L-lysine solution (0.1 mg/mL in H2O), incubate 5 min under the TC hood, aspirate, and allow the opened dish to dry under the hood before plating 3 x 106 HEK293T cells.
    2. Day 2: Add 30 µL of cation lipid-mediated transfection reagent to 0.75 mL antibiotic-free lipofection-optimized medium.
    3. In parallel, add 2 µg of pCL-Ampho Retrovirus Packaging Vector and 2 µg of pBABE-puro-hTERT plasmids to another 0.75 mL of antibiotic-free lipofection-optimized medium.
    4. Incubate for 5 min at RT.
    5. Mix the two dilutions in a 15 mL conical tube and incubate for 20 min at RT.
    6. Meanwhile, replace the HEK293T medium with 6 mL of lipofection-optimized medium supplemented with 10% FBS.
    7. Gently distribute the DNA complexes on the dish surface and incubate for 6 h to O/N in a humidified CO2 incubator.
    8. Day 3: Replace the medium with 7 mL of cDMEM and incubate for 48 h.
      NOTE: Starting from this step, work must be performed in a Biosafety level 3 (BSL3) tissue culture facility, following institutional rules.
    9. On day 5, collect the virus-containing medium and filter through a 0.22 µm syringe filter.
    10. Aliquot and store at -80 °C.
  2. Viral transduction
    1. Day 1: Plate low passage fibroblasts at 60% confluence in 2 wells of a 6-well plate.
    2. Day 2: Replace the medium with 1 mL of the previously produced pBABE-puro-hTERT retroviral preparation containing 8 µg/mL of polybrene and incubate for 12-16 h.
    3. Day 3: Replace the virus-containing medium with 2 mL of cDMEM.
    4. Day 4: After 24 h, start two 48 h rounds of puromycin selection (2 µg/mL).
      NOTE: The concentration should be empirically determined for each batch of antibiotic and cell type, and the lowest concentration should be selected to kill all cells within 4 days of selection.
    5. Day 8: Check that the uninfected control cells have all died. Replace the medium with cDMEM and let infected cells grow until confluent before passaging them 1:3. Let cells reach confluency and split again 1:3. At this stage, the cells can exit the BLS3 facility.
      NOTE: Prepare frozen aliquots as soon as possible. To ensure immortalization has occurred, passage the cells 5-6 times and score their morphology and duplication rates, which should not change with passages. Functionally compare immortalized cells to their primary counterparts, using the methods described below.

6. Fibroblasts characterization

  1. Phenotypically analyze the isolated cells for the expression of CAF/NF markers, and functionally characterize for their potential pro-oncogenic activities on tumor cells.
    NOTE: The qPCR oligonucleotides and antibodies optimized to assess marker expression levels at both RNA and protein levels are reported in Table 2 and Table of Materials, respectively. Beware that antibodies against fibroblast activation protein (FAP) are often non-specific. Make sure to include appropriate positive and negative controls31,32. Different methods can be used to assess the crosstalk between fibroblasts and tumor cells. Here, two alternative approaches are described, consisting of either treating tumor cells with conditioned medium (CM) derived from CAFs or NFs, or co-culturing fibroblasts and tumor cells. The efficacy of either approach to enhance the proliferation of tumor cells is described.

7. Preparation and concentration of conditioned medium

NOTE: Conditioned medium is concentrated and accurately dosed after collection to facilitate the comparison between different cells.

  1. Plate the cells at 70% confluence in a 15 cm dish in cDMEM.
  2. The following day, switch to 15 mL of starvation medium (DMEM with no FBS) and incubate for 48 h to produce the CM.
  3. Collect the CM, centrifuge at 300 x g for 5 min at RT, and filter through a 0.22 µm filter to eliminate cell debris and sterilize.
  4. Transfer to concentrating tubes (MWCO 10,000 Da), and centrifuge 20 min at 2000 x g and 4 °C, or according to the manufacturer's instructions, to obtain about 1 mL of the concentrated CM (conCM), i.e. 15 x concentration.
  5. Aliquot the conCM and store at -80 °C.
  6. Quantify the protein content of the collected conCM using a colorimetric protein assay.
    NOTE: The average concentration obtained is 0.5 and 2 µg/µL. Lower concentrations can still be used.

8. Proliferation assay

NOTE: Cell proliferation (using DU145 or LNCaP human PCa cell lines) was assessed using a live cell analysis instrument under two different settings, either treating the tumor cells with conCM, or co-cultivating them with CAFs or NFs. In this case, fluorescent tumor cells must be used. Representative results are shown in Figure 3.

  1. Proliferation assay upon treatment with conCM
    NOTE: This protocol is optimized for DU145 cells; different cells may require adjustments.
    1. Plate tumor cells in cDMEM in a 96-well plate (750 cells/well), considering at least 3 replicates per condition, and incubate O/N.
    2. Replace cDMEM with starvation medium, supplemented or not, with 50 µg/mL of conCM.
    3. Transfer the plate to the live cell analysis instrument chamber within the incubator.
    4. Let warm at 37 °C for 30 min, then start the first scanning.
    5. Use the phase contrast channel, choosing an appropriate objective and number of desired fields/well (10x objective and 5 fields/well are recommended), and standard scan type. Scan every 6 h for 4-5 days (duration must be empirically determined for conditions and cell types).
    6. Perform the analysis according to manufacturer's instructions (see Table of Materials).
    7. Calculate for each well (technical replicates for each condition) the fold change relative to its value at time zero. Generate the corresponding graphs and assess statistical significance using appropriate software.
  2. Proliferation assay upon co-culturing
    1. Co-plate 750 RFP-expressing DU145 cells and CAFs or NFs at a 1:3 ratio in cDMEM in a 96-well plate.
    2. The following day, switch to 2% FBS DMEM. Transfer the plate to the live cell analysis instrument chamber in the incubator and start standard scanning every 6 h for 4 days, using both the phase contrast and orange channel.
    3. Perform proliferation analysis according to manufacturer's instructions (see Table of Materials).
    4. Calculate for each well (technical replicates for each condition) the fold change relative to its value at time zero. Generate the corresponding graphs and assess statistical significance using appropriate software.

9. Wound healing migration assay

NOTE: Here, an automated version of the classical scratch assay33 is presented to measure cell migration, using a live cell analysis instrument.

  1. Plate tumor cells in a 96-well plate suitable for the live cell analysis instrument to obtain a confluent monolayer.
  2. The following day, treat the cells with 10 ug/mL of mitomycin C for 2 h.
    NOTE: This step is essential to avoid cell proliferation during the assay, which would confound the results.
  3. Apply the scratch on the wells following manufacturer's instructions (see Table of Materials).
  4. Wash with 100 µL of PBS to remove detached cells.
  5. Add starvation medium, with 50 mg/mL or without (control).
  6. Place the plate in the live cell analysis chamber in the incubator.
  7. After 30 min, program the recommended wound healing scanning protocol, every 4 h for 1 day or longer, depending on cells and conditions.
  8. Analyze the results according to manufacturer's instructions (see Table of Materials).

10. Anchorage-independent growth by soft agar assay

  1. Plate CAFs or NFs at 70% confluence in 12-well plates, leaving three empty wells as a control.
  2. The following day, prepare a 4x soft agar stock solution (3.6%) by adding 0.45 g of low-melting agar to 12.5 mL PBS in a 50 mL conical tube under sterile conditions.
  3. Dissolve in a microwave oven. Beware of excessive boiling that would cause the solution to concentrate.
  4. Cool down at 37 °C, then prepare a 1x working solution by diluting 1:4 with prewarmed cDMEM.
  5. Aspirate the medium from the 12-well plate and add 500 µL of 1x agar solution to each well.
  6. Let it solidify for 20 min at 4 °C, while storing the rest of the agar solution at 37 °C.
  7. Meanwhile, trypsinize the tumor cells and prepare a cell suspension of 2 x 104 cell/mL.
  8. Mix equal volumes of the cell suspension and the agar 1x solution by pipetting multiple times, and dispense 500 µL (i.e., 5000 cells) on top of the first agar layer in each well. Make sure to prepare at least a 10% excess of cell suspension.
  9. Let the agar solidify by incubating for 20 min at 4 °C.
  10. Add 1 mL of cDMEM to each well and renew it every other day by gently aspirating the medium from the edge of the well and adding the fresh medium to the center, almost dropwise to avoid displacing the soft agar layer.
  11. Incubate until easily visible colonies appear. DU145 cells usually take about 12 days, with slight variations.
  12. Discard the medium and stain colonies by adding 200 µL of nitroblue tetrazolium chloride solution (1 mg/mL in PBS). Incubate overnight at 37 °C in a humidified incubator.
  13. Once the colonies are stained, discard the dye solution and acquire images using a stereomicroscope. Place the plate on the microscope stage and set the magnification to its lowest value (0.8x) to ensure the entire well is visible. Use the coarse focus knob to bring the colonies into sharp focus, then adjust the lighting and mode settings before capturing the images.
  14. Use appropriate software34 to quantify the colony number and occupied area by following the steps provided in Supplementary File 1.
  15. Score the number and size distribution of the colonies (see Figure 4).

Access restricted. Please log in or start a trial to view this content.

Results

CAF and NF pairs from 7 high-grade PCa patients were successfully isolated with this protocol. Patients' age at surgery and Gleason scores are summarized in Table 3. To evaluate the purity of the derived fibroblast populations, passage two primary CAFs and NFs were detached and stained with the indicated fluorescent antibodies or with propidium iodide to assess apoptosis. Representative results from the subsequent FACS analysis are shown in Figure 2A...

Access restricted. Please log in or start a trial to view this content.

Discussion

The derivation and analysis of cells from PCa tissue provide a relevant experimental model, particularly considering that available animal models do not fully replicate human prostate anatomy and disease progression37. Chimpanzees' prostate glands are anatomically similar to humans but show a slow, stochastic disease progression, in addition to implying ethical limitations. Dogs differ significantly in prostate structure and pathobiology and develop sporadic, age-related prostate disease. Comm...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare no competing interests.

Acknowledgements

This work was supported by the Italian Cancer Research Association (AIRC), IG16930 and IG24851 to V.P; the Italian Ministry of University and Research (MIUR PRIN 2017 and 2022 to V.P.); the Truus and Gerrit van Riemsdijk Foundation, Liechtenstein, donation to V.P.; Piedmont Region (Deflect). A.S. was supported by an Italian Cancer Research Foundation (FIRC) post-doctoral fellowship, and L.A. was supported by Fondazione Umberto Veronesi. Figure 2 was created with BioRender.com.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
12 well plateSarstedt833921
24 well plateSarstedt833922
6 well plateSarstedt833920
96 well plateSarstedt833924
Anti-GAPDH Mouse mAb (6C5)Sigma AldrichCB1001Source: Mouse; Dilution for WB: 1:1000
aSMASigma AldrichA5228 Source: Mouse; Dilution for WB: 1:3000
CaveolinCell Signalling TechnologyCST3267Source: Rabbit; Dilution for WB: 1:1000
CD31-VioBlueMilteny Biotec130-119-980Flow Cytometry Ab, Endothelial cell marker
CD326-PE (EpCAM)Milteny Biotec130113-826Flow Cytometry Ab, Epithelial cell marker
CD45-FITCMilteny Biotec130-110769Flow Cytometry Ab, Pan leukocyte marker
CD90-APCMilteny Biotec130-114-903Flow Cytometry Ab, Fibroblast marker
Collagen VI (COL6A1)Abcamab182744Source: Rabbit; Dilution for WB: 1:1000
Conical tube 15 mLSarstedt62554502
Conical tube 50 mLSarstedt62547254
Cryopure 2 mL microtubesSarstedt72380992
Culture plate 100 mm diameter Corning353003
Culture plate 100 mm diameter Corning353025
Culture plate 60 mm diameter Corning353002
Dimethyl sulfoxide (DMSO)Sigma AldirchD8418Use in a Biological hood
Dulbecco’s Modified Eagle’s Medium (DMEM)Gibco11965092Store at 4 °C, use in a Biological hood
FAPAbcamab53066Source: Rabbit; Dilution for WB: 1:500
FcR Blocking Reagent, humanMilteny Biotec130-059-901Fc Blocker
Fetal Bovine Serum (FBS)Gibco16000044Store at 4 °C, use in a Biological hood
Filtered tips 10 µLSarstedt703010255
Filtered tips 100 µLSarstedt703030255
Filtered tips 1000 µLSarstedt703060255
Filtered tips 20 µLSarstedt703030265
Filtered tips 200 µLSarstedt703031255
Filtropur S Plus 0,20 µm Sarstedt831826102
Forcep2Biol1102412
FSP1/S100A4Cell Signalling TechnologyD9F9D (13018)Source: Rabbit; Dilution for WB: 1:2000
IL6Abclonal technologyA0286Source: Rabbit; Dilution for WB: 1:1000
ImageJNational Inst. of Healthversion 1.53cSoftware for image analysis
incucyte imagelock 96-well plateSartoriousBA-04857
Incucyte® SX5SartoriousSX5Live cell analysis instrument 
Lipofectamine 2000 Transfection ReagentThermoFisher Scientific11668019cation lipid-mediated transfection reagent
MACS® Tissue Storage SolutionMilteny Biotec130-100-008
Microplate reader (600 nm absorbance)PromegaGM3500
Microtubes 1.5 mL Sarstedt7269001
NcadAbcamab18203Source: Rabbit; Dilution for WB: 1:1000
Nitro Blue Tetrazolium Sigma Aldirchn5514
Parafilm Sigma AldirchHS234526B
pBABE-puro-hTERTAddgene1771Store at -20 °C, use in a Biological hood
pCL-AmphoNovus Biological NBP2-29541Store at -20 °C, use in a Biological hood
PDGFRBSanta Cruzsc-432Source: Rabbit; Dilution for WB: 1:1000
Penicillin-Streptomycin (PS, 10,000 μg/mL) Gibco15140122Store at 4 °C, use in a Biological hood
Phase contrast microscope Olympus BX42
Phosphate Buffered Saline (PBS)HomemadeNaCl, 137 mM; KCl, 2.7 mM; Na2HPO4, 10 mM;KH2PO4, 1.8 mM. Autoclave and Store at RT
Poly-L-lysine solutionSigma AldirchP8920Store at 4 °C, use in a Biological hood
Puromycin dihydrochlorideSigma AldirchP8833
Secura Semi Micro BalanceSartoriusSECURA125-1S
Serological pipette 10 mL Sarstedt861254001
Serological pipette 2 mL Sarstedt861252001
Serological pipette 25 mL Sarstedt861256001
Serological pipette 5 mL Sarstedt861253001
STAT3CST9139Source: Mouse; Dilution for WB: 1:1000
STAT3 Y705CST9131Source: Rabbit; Dilution for WB: 1:1000
stereomicroscopeLeicaMZ125
Syringe 10 mLPentaferte00202260D12
TermoMixerEppendorph22331
Trypsin-EDTA (0.5%), no phenol redGibco15400054
VimSanta Cruzsc-6260Source: Mouse; Dilution for WB: 1:2000
Vivaspin 20 centrifugal concentrator Sigma AldirchZ614602MWCO 10,000 Da 
Wagner scissors2Biol14070-12

References

  1. Bray, F. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74 (6), 229-263 (2024).
  2. Yadav, S. S., Stockert, J. A., Hackert, V., Yadav, K. K., Tewari, A. K. Intratumor heterogeneity in prostate cancer. Urol Oncol. 36 (8), 349-360 (2018).
  3. Owen, J. S., Clayton, A., Pearson, H. B. Cancer-associated fibroblast heterogeneity, activation and function: Implications for prostate cancer. Biomolecules. 13 (1), 67(2023).
  4. Ge, R., Wang, Z., Cheng, L. Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. NPJ Precis Oncol. 6, 1-8 (2022).
  5. Pejčić, T., Todorović, Z., Đurašević, S., Popović, L. Mechanisms of prostate cancer cells survival and their therapeutic targeting. Int J Mol Sci. 24 (3), 2939(2023).
  6. Shoag, J., Barbieri, C. Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl. 18 (4), 543-548 (2016).
  7. Segura-Moreno, Y. Y., Sanabria-Salas, M. C., Varela, R., Mesa, J. A., Serrano, M. L. Decoding the heterogeneous landscape in the development of prostate cancer. Oncol Lett. 21 (5), 376(2021).
  8. Hägglöf, C., Bergh, A. The stroma-a key regulator in prostate function and malignancy. Cancers (Basel. 4 (2), 531-548 (2012).
  9. Teng, L. K. H., et al. Mast cell-derived SAMD14 is a novel regulator of the human prostate tumor microenvironment. Cancers (Basel). 13 (6), 1-25 (2021).
  10. Galbo, P. M., Zang, X., Zheng, D. Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance. Clin Cancer Res. 27 (9), 2636-2647 (2021).
  11. Mao, X., et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol Cancer. 20 (1), 1-30 (2021).
  12. Pederzoli, F., et al. Stromal cells in prostate cancer pathobiology: Friends or foes. Br J Cancer. 128 (6), 930-939 (2022).
  13. Sasaki, T., Franco, O. E., Hayward, S. W. Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo. Differentiation. 96, 40-48 (2017).
  14. Cirri, P., Chiarugi, P. Cancer-associated fibroblasts, and tumor cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev. 31 (1-2), 195-208 (2012).
  15. Lu, P., Weaver, V. M., Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol. 196 (4), 395-406 (2012).
  16. Kahounová, Z. The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition. Cytometry A. 93 (9), 941-951 (2018).
  17. Giannoni, E., et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 70 (17), 6945-6956 (2010).
  18. Paland, N., et al. Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Mol Cancer Res. 7 (8), 1212-1235 (2009).
  19. Jaeschke, A., et al. Cancer-associated fibroblasts of the prostate promote a compliant and more invasive phenotype in benign prostate epithelial cells. Mater Today Bio. 8, 100073(2020).
  20. Ellem, S. J., et al. A pro-tumourigenic loop at the human prostate tumor interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. J Pathol. 234 (1), 86-98 (2014).
  21. Lawrence, M. G., et al. Alterations in the methylome of the stromal tumor microenvironment signal the presence and severity of prostate cancer. Clin Epigenetics. 12 (1), 48(2020).
  22. Nguyen, E. V. Proteomic profiling of human prostate cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment. Mol Cell Proteomics. 18 (7), 1410-1427 (2019).
  23. Smith, M. C., Goddard, E. T., Perusina Lanfranca, M., Davido, D. J. hTERT extends the life of human fibroblasts without compromising type I interferon signaling. PLoS One. 8 (3), e58233(2013).
  24. Kay, E. J., et al. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. Nat Metab. 4 (6), 693-710 (2022).
  25. Huynh, L. M., Ahlering, T. E. Robot-assisted radical prostatectomy: A step-by-step guide. J Endourol. 32, S28-S32 (2018).
  26. Srigley, J. R., et al. Protocol for the examination of specimens from patients with carcinoma of the prostate gland with guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees. , https://documents.cap.org/protocols/cp-prostate-2017-v4020.pdf (2017).
  27. Goldblum, J. R., Lamps, L. W., McKenney, J. K. Rosai and Ackerman's Surgical Pathology E-Book. , https://books.google.it/books/about/Rosai_and_Ackerman_s_Surgical_Pathology.html?id=7ZEDwAAQBAJ (2024).
  28. Montironi, R., Beltran, A. L., Mazzucchelli, R., Cheng, L., Scarpelli, M. Handling of radical prostatectomy specimens: Total embedding with large-format histology. Int J Breast. 2012, (2012).
  29. Arcega, R. S., Woo, J. S., Xu, H. Performing and cutting frozen sections. Methods Mol Biol. 1897, 279-288 (2019).
  30. IARC. WHO Classification of Tumors, 5th edition, volume 8: Urinary and male genital tumors. , https://www.iarc.who.int/news-events/who-classification-of-tumours-5th-edition-volume-8-urinary-and-male-genital-tumours/ (2025).
  31. Sfanos, K. S., et al. If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease. Asian J Urol. 6 (1), 10-25 (2019).
  32. Brennen, W. N., et al. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy. 13 (2), 155-175 (2021).
  33. Pinto, B. I., Cruz, N. D., Lujan, O. R., Propper, C. R., Kellar, R. S. In vitro scratch assay to demonstrate effects of arsenic on skin cell migration. J Vis Exp. (133), e58838(2019).
  34. Schneider, C. A., Rasband, W. S., Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9 (7), 671-675 (2012).
  35. Sauzay, C., Voutetakis, K., Chatziioannou, A. A., Chevet, E., Avril, T. CD90/Thy-1, a cancer-associated cell surface signaling molecule. Front Cell Dev Biol. 7, 444743(2019).
  36. True, L. D., et al. CD90/THY1 is over-expressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol. 23 (10), 1346(2010).
  37. Strand, D. W., Aaron, L. T., Henry, G., Franco, O. E., Hayward, S. W. Isolation and analysis of discreet human prostate cellular populations. Differentiation. 91 (4-5), 139(2015).
  38. Krönig, M., et al. Cell type-specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity. Oncotarget. 6 (2), 1302-1314 (2014).
  39. Goldstein, A. S., et al. Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc. 6 (5), 656-667 (2011).
  40. Kassen, A., et al. Stromal cells of the human prostate: Initial isolation and characterization. Prostate. 28 (2), 89-97 (1996).
  41. Linxweiler, J., et al. Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. Sci Rep. 10 (1), 12575(2020).
  42. Liu, A. Y., et al. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A. 94 (20), 10705-10710 (1997).
  43. Olumi, A., et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59 (19), 5002(1999).
  44. Luthold, C., Hallal, T., Labbé, D. P., Bordeleau, F. The extracellular matrix stiffening: A trigger of prostate cancer progression and castration resistance. Cancers (Basel). 14 (12), 2887(2022).
  45. Wang, H., Van Blitterswijk, C. A., Bertrand-De Haas, M., Schuurman, A. H., Lamme, E. N. Improved enzymatic isolation of fibroblasts for the creation of autologous skin substitutes. In Vitro Cell Dev Biol Anim. 40 (8-9), 268-277 (2004).
  46. Yun, Y. R., et al. Fibroblast growth factors: Biology, function, and application for tissue regeneration. J Tissue Eng. 1 (1), 1-18 (2010).
  47. Baranyi, U., et al. Primary human fibroblasts in culture switch to a myofibroblast-like phenotype independently of TGF beta. Cells. 8 (7), 721(2019).
  48. Ortiz-Otero, N., et al. Cancer-associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancer metastatic progression. Oncotarget. 11 (12), 1037-1050 (2020).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Prostate Cancer FibroblastsFibroblast IsolationTumor MicroenvironmentConditioned MediaAnchorage Independent GrowthSoft Agar AssayFibroblast Co CultureTumor StromaFibroblast Characterization

Related Articles